Modern antioestrogens and the coming revolution in women's health care
review
OA: closed
public-domain-us
AI-generated summary
This review discusses traditional and modern antioestrogens and SERMs, their effects on breast, uterus, bone, and lipids, and their future use in gynaecological conditions and breast cancer.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This review will focus on antioestrogens and selective oestrogen receptor modulators (SERMS). The more traditional SERMS, clomiphene citrate and tamoxifen, will be reviewed along with such modern drugs as raloxifene and faslodex, with emphasis upon their actions on breast, uterus, bone and lipids. The future potential of these medications, in the management of oestrogen-dependent gynaecological conditions such as endometriosis, dysfunctional uterine bleeding, fibroids and breast cancer will be discussed.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-08T06:08:32.324769+00:00
- pubmed
- last seen: 2026-05-13T22:10:24.024533+00:00
- unpaywall
- last seen: 2026-06-13T06:42:57.164913+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine